Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer. The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis. Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials. Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy. Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR.
View Top Employees from Sareum LtdWebsite | http://www.sareum.com |
Ticker | SAR |
Revenue | $174000 |
Employees | 45 (45 on RocketReach) |
Founded | 2003 |
Phone | +44 1223 497700 |
Fax | +44 1223 497701 |
Industry | Biotechnology, Manufacturing General, Cancer Research, Manufacturing, Oncology, Drug Discovery, Auto-Immune Disease |
Competitors | 4Sc Ag, Amedis Pharmaceuticals Ltd, Beactica Therapeutics, ImmuPharma PLC, Infinity Pharmaceuticals |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Sareum Ltd employee's phone or email?
The Sareum Ltd annual revenue was $174000 in 2024.
45 people are employed at Sareum Ltd.
The NAICS codes for Sareum Ltd are [32, 325, 3254, 32541].
The SIC codes for Sareum Ltd are [28, 283].